Navigation Links
Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Date:9/5/2012

front, milestone and yearly R&D payments. Since December 2010, Dr. Zanganeh has served as the Company's Chief of Staff and Vice President, Business Development. In her role, she led the negotiations with Janssen, valued at up to $975 million (based on the successful completion of various milestones). She spearheaded the hiring of key corporate executives and she was responsible for expanding the company employees from 50 to over 170 today. Dr. Zanganeh also served as Director General for the French government initiative biocluster project, establishing alliances and developing small life science businesses regionally in France. She also served as worldwide Vice President of Training & Education and President Director General for Europe, Middle East and Africa for Computer Motion Inc., the world initiator of medical robotics. There she spearheaded the use of robotics in the operating room, a concept that has revolutionized the medical and surgical industry.

Paula S. Boultbee joined Pharmacyclics as the Executive Vice President of Sales & Marketing. She has more than 20 years of experience in oncology commercialization including extensive global and USA launch experience gained from the brands Glivec/Gleevec (imatinib), Camptosar (irinotecan) and Aromasin (exemestane). Her expertise has been acquired through increased responsibilities in both small and large pharmaceutical companies. While at Amgen she led the life cycle management efforts of the erythropoietic proteins and EGFR inhibitor Vectibix, and the pre-marketing efforts of a number of preclinical molecules, companion diagnostics, and devices. At Pharmacia (Pfizer), she held positions with growing responsibility in sales, brand management, and country and regional leadership roles. During her tenure at Novartis she led the global launch for the corporate flagship product Glivec/Gleevec: a product that is today helping thousands of patients to live a fuller life.

Joshua T. Brumm joined
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)...  Aurobindo Pharma USA is ... mg 100-count bottles to the consumer level. The product ... Empty capsules could result in missed dose(s) ... range from no effect, short term reduction in efficacy, ... seizures) that could be life-threatening. Aurobindo Pharma ...
(Date:11/22/2014)... MIAMI , Nov. 22, 2014  New data ... for the most common form of female sexual dysfunction, ... cognitive function or driving performance in premenopausal women when ... Sexual Medicine Society of North America,s ... Miami . SMSNA accepted ...
(Date:11/22/2014)... noviembre de 2014  BioClinica®, Inc., un proveedor ... tecnologías eClinical, ha indicado un aumento de la ... el seguimiento basado en el riesgo en los ... del seguimiento basado en el riesgo más allá ... seguimiento o cambio de los métodos de seguimiento. ...
Breaking Medicine Technology:Aurobindo Pharma USA, Inc. Issues Voluntary Nationwide Recall of Northstar Label Gabapentin Capsules, USP 300 mg Due to Complaints of Empty Capsules 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... June 1, 2011 Esperance ... of a $7.5 million Series B financing. Proceeds from ... EP-100, the lead cancer-targeting drug candidate from Esperance,s Cationic ... of the Company,s pipeline. Sanofi led the Series B ...
... June 1, 2011 MMRGlobal, Inc. (OTCBB: ... www.deutsch-boerse.com ) have entered into an agreement ... health IT products and services, including MMRPro for healthcare ... Health Record (PHR) ( www.mmrvideos.com ), on the ...
Cached Medicine Technology:Esperance Pharmaceuticals Completes $7.5 Million Series B Financing 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 2VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 3VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 4VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia 5
(Date:11/24/2014)... California (PRWEB) November 24, 2014 ... USD 6.19 billion by 2020, according to a ... incidence rates of cardiac arrhythmias clubbed with growing ... of this market. Though still in the budding ... significant rise in usage rates in the recent ...
(Date:11/24/2014)... CHICAGO (PRWEB) November 24, 2014 ... VolparaAnalytics version 1.2 at the 100th Annual Meeting ... November 30-December 5, 2014 (RSNA Booth 1752 – ... version of VolparaAnalytics and the rest of its ... VolparaDensity and VolparaDoseRT, which enable personalized measurements of ...
(Date:11/24/2014)... Virginia (PRWEB) November 24, 2014 Residents ... center stage in this year’s SENIORS GOT TALENT, an ... Guide. , From piano players to classic crooners, to ... clear that older adults are indeed living young. , ... competition because there’s a cash prize, has always been ...
(Date:11/24/2014)... Olaparib functions as a chemical of ... one of the first PARP inhibitors. Sufferers with BRCA1/2 ... of melanoma, and are often immune to other types ... malignancies a exclusive weaknesses, as the tissues of melanoma ... and allow them to proceed splitting. This implies that ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
Breaking Medicine News(10 mins):Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3
... the latest study by the Mayo clinic, injecting an anesthetic ... ,The new study that is being presented today ... the American Urological Association, in San Diego, had found that ... of pain during their biopsy. It was explained that the ...
... disease of the rich and comfortably off in India has now ... classes in India.// , The disease has become so ... with the diabetic population in the country reaching a count of ... to more than double. ,International attention has been drawn ...
... caused drastic increase in cancer among kids across Europe. They ... cases of cancer in kids identified between 1978 and 1997 ... to the results, there was an increase by an average ... in children under the age of 14. ,Majority ...
... According to a review that was published in the Friday’s issue ... reduce their risk of fractures in the later years.// ... got by the age of 18 years. Hence, it is expected ... effects of age-related bone loss and osteoporosis. ,The results ...
... used to treat migraine headaches can be effective in ... zolmitriptan targets nerves that carry pain signals, Dr. Peter ... said.// ,Cluster headaches are not as common as ... 92 patients with cluster headaches. In the final analysis ...
... wells near the Queen’s Balmoral Castle in Scotland kills cancer ... biochemistry at the University of Maribor in Slovenia said that ... and compared them to those placed in normal lab water. ... of colon cancer cells 62.5 percent more quickly than normal ...
Cached Medicine News:Health News:India’s Silent Killer on the Prow 2Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2
CTAD tubes contain theophylline, adenosine and dipyridamol. Coagulation and DTAD tubes are for examination of coagulation parameters....
... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
Inquire...
Inquire...
Medicine Products: